Genentech, Biogen appeal US judgement favouring GSKin anti-CD20 Mab infringement suit
This article was originally published in Scrip
Executive Summary
As expected, Genentech and its partner Biogen Idec have appealed the judgement that favoursGlaxoSmithKline in a patent infringement case involving the anti-CD20 monoclonal antibody Arzerra (obatumumab).